Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Transl Med
Päätekijät: Yang, Lu, Zhang, Youyou, Shan, Weiwei, Hu, Zhongyi, Yuan, Jiao, Pi, Jingjiang, Wang, Yueying, Fan, Lingling, Tang, Zhaoqing, Li, Chunsheng, Hu, Xiaowen, Tanyi, Janos L., Fan, Yi, Huang, Qihong, Montone, Kathleen, Dang, Chi V., Zhang, Lin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705017/
https://ncbi.nlm.nih.gov/pubmed/28747513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal1645
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia